3 ms·
The final quote raises the interesting question: > Peter Bach, director for the center for health policy and outcomes at Memorial Sloan Kettering Cancer Center
by hombre_fatal 7y ago
The final quote raises the interesting question:
> Peter Bach, director for the center for health policy and outcomes at Memorial Sloan Kettering Cancer Center, is troubled by Zolgensma’s price and believes ICER’s updated cost-effectiveness analysis takes too many liberties.
> “You can look at this in either of two ways. It’s an amazing treatment and only a few kids will need it so a million here and million there is not worth more than shoulder shrug,” he said. “Or we have a big problem. Biopharma has been entirely redirected to rare diseases because the market will tolerate any price and the FDA will require pretty minimal data.”
- ThrowawayIP 7y agoThat quote just states that some corporate board rooms have found a local maximum in the profit vs (time to market & R&D costs). Pharma companies do not operate by any moral mandate but are only seeking profit.